Jasper Therapeutics (NASDAQ:JSPR) Price Target Cut to $48.00 by Analysts at Royal Bank of Canada

Jasper Therapeutics (NASDAQ:JSPR) had its target price reduced by Royal Bank of Canada from $68.00 to $48.00 in a research report report published on Thursday,Benzinga reports. They currently have an outperform rating on the stock.

Other equities analysts have also issued reports about the company. JMP Securities reaffirmed a “market outperform” rating and issued a $70.00 price objective on shares of Jasper Therapeutics in a research note on Monday. HC Wainwright restated a “buy” rating and set a $65.00 price objective on shares of Jasper Therapeutics in a research note on Thursday, October 24th. Finally, BMO Capital Markets started coverage on Jasper Therapeutics in a research note on Friday, December 6th. They set an “outperform” rating and a $63.00 target price for the company. Ten research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $70.88.

Jasper Therapeutics Stock Performance

JSPR opened at $6.99 on Thursday. The stock has a market capitalization of $104.86 million, a PE ratio of -1.47 and a beta of 2.18. The company’s 50 day simple moving average is $21.66 and its 200 day simple moving average is $20.37. Jasper Therapeutics has a 1 year low of $6.61 and a 1 year high of $31.01.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of JSPR. Samsara BioCapital LLC lifted its holdings in Jasper Therapeutics by 11.4% in the third quarter. Samsara BioCapital LLC now owns 584,642 shares of the company’s stock worth $10,997,000 after acquiring an additional 59,642 shares during the last quarter. Wellington Management Group LLP acquired a new stake in shares of Jasper Therapeutics during the 3rd quarter worth approximately $447,000. Ally Bridge Group NY LLC lifted its holdings in shares of Jasper Therapeutics by 82.7% in the 3rd quarter. Ally Bridge Group NY LLC now owns 399,466 shares of the company’s stock worth $7,514,000 after purchasing an additional 180,852 shares during the last quarter. Braidwell LP acquired a new position in Jasper Therapeutics during the 3rd quarter valued at approximately $9,091,000. Finally, FMR LLC bought a new position in Jasper Therapeutics during the 3rd quarter worth $722,000. 79.85% of the stock is owned by institutional investors and hedge funds.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.